If it were assumed that KRAS were mutated first and SMAD4 and TP53 mutations followed, a likely explanation would be that a subset of tumor cells lost their mutant KRAS allele through loss of heterozygosity (LOH). This evidence concerns the gene KRAS and neoplasm.